Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNOS-PV02
- Development stage
- Phase 2
- Lead developer
- Geneos Therapeutics
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
GNOS-PV02 is a personalized therapeutic cancer vaccine (PTCV) developed by Geneos Therapeutics. It is a DNA plasmid-based vaccine encoding up to 40 patient-specific tumor neoantigens, designed to elicit strong immune responses against cancer cells bearing these unique mutated proteins. The vaccine is administered in combination with a plasmid-encoded interleukin-12 (IL-12) cytokine adjuvant and pembrolizumab, a PD-1 inhibitor. The mechanism involves the induction of tumor-infiltrating lymphocytes (TILs), particularly CD8+ T-effector memory cells with cytotoxic phenotypes, which target and kill tumor cells expressing the encoded neoantigens. Clinical trials have focused on advanced hepatocellular carcinoma (HCC), where the combination has demonstrated safety, immunogenicity, and promising efficacy as measured by objective response rate[1][2][3][4][5][6][8].
- Other names
- personalized neoantigen DNA vaccine GNOS-PV02
02
Targets
pMHC-I (Peptide–MHC class I complex)TCR (T cell antigen receptor complex)IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on GNOS-PV02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNOS-PV02.